AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02583451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 2.5 mg
Description: 2.5 tablet taken orally at bedtime.
Study NCT02583451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: 5 mg tablet taken orally at bedtime.
Study NCT02583451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: 10 mg tablet taken orally at bedtime.
Study NCT00890383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetrastarch (Voluven)
Description: Goals directed volume therapy for severe trauma resuscitation
Study NCT03936205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
Study NCT01786993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing
Description: Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
Study NCT01786993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Biventricular Pacing
Description: Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
Study NCT03896022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure with Beads
Description: Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
Study NCT03896022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture with Needles
Description: Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
Study NCT00488839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 20 mg
Description: Placebo capsule for IPX056 20 mg
Study NCT00488839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IPX056 40 mg
Description: Placebo capsule for IPX056 40 mg
Study NCT03896022 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Adhesive Disks
Description: Single-use adhesive disks without needles or beads.
Study NCT00774202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan, Cyclophosphamide, Vincristine, Prednisone
Description: 'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
Study NCT00774202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher Dose of Rituximab
Description: rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
Study NCT04070599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
Study NCT01954576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A
Study NCT01954576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Study NCT01954576 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Study NCT04182178 — intervention group
Intervention type: OTHER
Intervention: 10 years follow up
Description: Questionnaires
Study NCT03504319 — intervention group
Intervention type: OTHER
Intervention: Exposure to high-fat smoothie
Description: Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
Study NCT02437539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NOTA-AE 105
Study NCT02437539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography scans
Description: Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
Study NCT01223313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Woman's Condom
Description: The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
Study NCT02882802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
Study NCT02882802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Recovery Education Class
Description: Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
Study NCT04139811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pars Plana Vitrectomy
Description: vitrectomy with and without ILM peeling
Study NCT01070004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real driving situation
Description: Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
Study NCT01070004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving simulator
Description: 15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
Study NCT00647231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT-500 Topical Patch
Description: Treatment with Ketoprofen Topical Patch
Study NCT00647231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Treatment with placebo patch
Study NCT03856424 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modality 3
Description: High-flow oxygen
Study NCT03471689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants will be trained to use mindfulness meditation to reduce pain perception.
Study NCT03471689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive reappraisal
Description: Participants will be trained to use positive reappraisal to reduce pain perception.
Study NCT02235766 — intervention group
Intervention type: OTHER
Intervention: Echocardiographic assessment
Study NCT04083989 — intervention group
Intervention type: OTHER
Intervention: Integrative medicine-based multimodal treatment
Description: Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
Study NCT01863017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT01863017 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study NCT04529577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His-bundle pacing
Description: A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup.
Study NCT03054844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine will be administered before administration of midazolam.
Study NCT03054844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and midazolam (PREMIX)
Description: Lidocaine will be administered as a mixture with midazolam.
Study NCT03054844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
Study NCT01977118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: streptokinase
Description: 50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
Study NCT01977118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline irrigation
Description: 100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
Study NCT05287802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance and proprioception exercises
Description: Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAQTA™
Description: One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAQTA™
Description: One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR II™
Description: One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR II™
Description: One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
Study NCT05287802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises program
Description: Isometric exercises for the quadriceps and hamstrings at home
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIBERIX™
Description: One HIBERIX™ 0.5 mL IM dosing at Visit 5.
Study NCT03893448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: One HIBERIX™ 0.5 mL IM dosing at Visit 5.
Study NCT01547650 — intervention group
Intervention type: OTHER
Intervention: Calculated CVP by using cardiac echogram
Description: Before and after the correction of plasma volume
Study NCT02378467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline (HS)
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Study NCT02378467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS)
Description: Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Study NCT04219800 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient-centered counselling and written material
Description: Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
Study NCT04219800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered counselling and written material
Description: Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
Study NCT04219800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: 1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics.
Study NCT00554177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicane (mifepristone)
Description: 2 doses of 1200mg, Administered 2-3 days apart
Study NCT00554177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 1200mg, administered 2-3 days apart
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Given PO
Study NCT00061945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT04696224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
Study NCT04696224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
Study NCT04540809 — intervention group
Intervention type: OTHER
Intervention: Assessment of strength, proprioception, skill and coordination of the hand
Description: Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
Study NCT00489632 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
Study NCT03700983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-PEITC jelly
Description: an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
Study NCT05132062 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
Study NCT03232359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: immature platelets fraction
Description: IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
Study NCT03215680 — intervention group
Intervention type: OTHER
Intervention: Climate
Description: Hot and temperate climate
Study NCT02270320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.